Niagen Bioscience Inc (NAGE) 10-Year Financial Performance & Capital Metrics

NAGE • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AboutNiagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.Show more

Revenue $100M +19.2%
EBITDA $9M +336.5%
Net Income $9M +273.1%
EPS (Diluted) 0.11 +266.9%
Gross Margin 61.84% +1.8%
EBITDA Margin 9.25% +298.5%
Operating Margin 7.76% +215.8%
Net Margin 8.58% +245.3%
ROE 22.94% +232.7%
ROIC 131.74% +369.8%
Debt/Equity 0.06 -50.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong Piotroski F-Score: 7/9
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 16.6%
✓Efficient asset utilization: 1.5x turnover

✗Weaknesses

✗Weak momentum: RS Rating 12 (bottom 12%)
✗Trading more than 30% below 52-week high
✗Expensive at 10.9x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y20.59%

5Y16.56%

3Y13.87%

TTM36.04%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM1275.69%

EPS CAGR

10Y-

5Y-

3Y-

TTM1172.49%

ROCE

10Y Avg-52.19%

5Y Avg-43.59%

3Y Avg-15.46%

Latest18.25%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	17.88M	21.66M	21.2M	31.56M	46.29M	59.26M	67.45M	72.05M	83.57M	99.6M
Revenue Growth %	0.17%	0.21%	-0.02%	0.49%	0.47%	0.28%	0.14%	0.07%	0.16%	0.19%
Cost of Goods Sold+	10.35M	11.27M	10.72M	15.5M	20.52M	23.98M	25.96M	29.25M	32.79M	38.01M
COGS % of Revenue	0.58%	0.52%	0.51%	0.49%	0.44%	0.4%	0.38%	0.41%	0.39%	0.38%
Gross Profit+	7.53M	10.39M	10.48M	16.05M	25.77M	35.27M	41.49M	42.8M	50.78M	61.59M
Gross Margin %	0.42%	0.48%	0.49%	0.51%	0.56%	0.6%	0.62%	0.59%	0.61%	0.62%
Gross Profit Growth %	0.41%	0.38%	0.01%	0.53%	0.61%	0.37%	0.18%	0.03%	0.19%	0.21%
Operating Expenses+	9.6M	13.3M	26.85M	49.23M	57.07M	55.13M	68.56M	61.42M	56.38M	53.86M
OpEx % of Revenue	0.54%	0.61%	1.27%	1.56%	1.23%	0.93%	1.02%	0.85%	0.67%	0.54%
Selling, General & Admin	8.71M	10.77M	22.1M	43.67M	52.52M	51.71M	64.73M	56.6M	51.42M	47.84M
SG&A % of Revenue	0.49%	0.5%	1.04%	1.38%	1.13%	0.87%	0.96%	0.79%	0.62%	0.48%
Research & Development	891.6K	2.52M	4.01M	5.48M	4.42M	3.42M	3.83M	4.83M	4.96M	6.02M
R&D % of Revenue	0.05%	0.12%	0.19%	0.17%	0.1%	0.06%	0.06%	0.07%	0.06%	0.06%
Other Operating Expenses	0	0	746K	75K	125K	0	0	0	0	0
Operating Income+	-2.07M	-2.91M	-16.38M	-33.17M	-31.3M	-19.85M	-27.07M	-18.63M	-5.6M	7.73M
Operating Margin %	-0.12%	-0.13%	-0.77%	-1.05%	-0.68%	-0.34%	-0.4%	-0.26%	-0.07%	0.08%
Operating Income Growth %	0.61%	-0.41%	-4.64%	-1.03%	0.06%	0.37%	-0.36%	0.31%	0.7%	2.38%
EBITDA+	-1.74M	-2.49M	-15.66M	-32.33M	-29.78M	-18.34M	-25.45M	-16.74M	-3.89M	9.21M
EBITDA Margin %	-0.1%	-0.11%	-0.74%	-1.02%	-0.64%	-0.31%	-0.38%	-0.23%	-0.05%	0.09%
EBITDA Growth %	0.65%	-0.43%	-5.3%	-1.06%	0.08%	0.38%	-0.39%	0.34%	0.77%	3.37%
D&A (Non-Cash Add-back)	330.55K	419.56K	716K	842K	1.52M	1.51M	1.63M	1.88M	1.71M	1.48M
EBIT	-2.07M	-2.91M	-16.38M	-33.17M	-31.3M	-19.85M	-27.07M	-18.63M	-5.6M	7.73M
Net Interest Income+	-612.71K	-333.29K	-153K	-79K	-847K	-71K	-55K	3K	661K	1.13M
Interest Income	3.33K	2.25K	0	0	0	0	0	3K	661K	1.13M
Interest Expense	616.03K	371.9K	153K	79K	847K	71K	55K	0	0	0
Other Income/Expense	-566.92K	-646.38K	-153K	-144K	-847K	-71K	-55K	2.09M	661K	1.13M
Pretax Income+	-2.63M	-3.55M	-16.53M	-33.32M	-32.15M	-19.93M	-27.13M	-16.54M	-4.94M	8.86M
Pretax Margin %	-0.15%	-0.16%	-0.78%	-1.06%	-0.69%	-0.34%	-0.4%	-0.23%	-0.06%	0.09%
Income Tax+	4.53K	0	0	0	0	0	0	0	0	305K
Effective Tax Rate %	1.05%	0.82%	0.69%	1%	1%	1%	1%	1%	1%	0.97%
Net Income+	-2.77M	-2.93M	-11.38M	-33.32M	-32.15M	-19.93M	-27.13M	-16.54M	-4.94M	8.55M
Net Margin %	-0.15%	-0.14%	-0.54%	-1.06%	-0.69%	-0.34%	-0.4%	-0.23%	-0.06%	0.09%
Net Income Growth %	0.49%	-0.06%	-2.89%	-1.93%	0.04%	0.38%	-0.36%	0.39%	0.7%	2.73%
Net Income (Continuing)	-2.64M	-3.55M	-16.53M	-33.32M	-32.15M	-19.93M	-27.13M	-16.54M	-4.94M	8.55M
Discontinued Operations	-133.53K	623.41K	5.15M	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.08	-0.08	-0.26	-0.61	-0.56	-0.33	-0.40	-0.24	-0.07	0.11
EPS Growth %	0.49%	-0.02%	-2.31%	-1.35%	0.08%	0.41%	-0.21%	0.4%	0.73%	2.67%
EPS (Basic)	-0.08	-0.08	-0.26	-0.61	-0.56	-0.33	-0.40	-0.24	-0.07	0.10
Diluted Shares Outstanding	35.88M	37.29M	44.6M	55.01M	57.06M	61.07M	67.19M	69.73M	74.98M	79.72M
Basic Shares Outstanding	35.88M	37.29M	44.6M	55.01M	57.06M	61.07M	67.19M	68.92M	70.54M	85.42M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	16.55M	15.74M	57.18M	36.53M	33.52M	32.22M	48.91M	46.57M	49.53M	64.1M
Cash & Short-Term Investments	5.55M	1.64M	45.39M	22.42M	18.61M	16.5M	28.02M	20.29M	27.17M	44.51M
Cash Only	5.55M	1.64M	45.39M	22.42M	18.61M	16.5M	28.02M	20.29M	27.17M	44.51M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	2.45M	5.85M	5.34M	4.42M	2.17M	2.69M	5.23M	8.48M	5.23M	7.77M
Days Sales Outstanding	50.01	98.59	91.9	51.07	17.15	16.59	28.28	42.97	22.86	28.47
Inventory	8.17M	7.91M	5.8M	8.25M	11.54M	11.68M	13.6M	14.68M	14.53M	9.19M
Days Inventory Outstanding	288.25	256.17	197.27	194.23	205.16	177.8	191.24	183.13	161.68	88.27
Other Current Assets	0	18.32K	0	877K	200K	200K	200K	3.12M	2.6M	2.63M
Total Non-Current Assets+	2.2M	4.01M	5.54M	5.7M	6.73M	6.14M	8.94M	7.49M	5.43M	4.18M
Property, Plant & Equipment	1.79M	1.78M	2.87M	3.58M	4.66M	4.43M	7.36M	6.32M	4.54M	3.45M
Fixed Asset Turnover	10.00x	12.18x	7.38x	8.80x	9.94x	13.37x	9.17x	11.40x	18.42x	28.88x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	354K	486K	1.65M	1.55M	1.31M	1.08M	857K	671K	510K	359K
Long-Term Investments	0	20.32K	0	0	0	0	0	0	0	0
Other Non-Current Assets	58.88K	1.73M	1.02M	566K	762K	625K	723K	497K	383K	368K
Total Assets+	18.75M	19.75M	62.72M	42.23M	40.25M	38.36M	57.84M	54.06M	54.96M	68.28M
Asset Turnover	0.95x	1.10x	0.34x	0.75x	1.15x	1.54x	1.17x	1.33x	1.52x	1.46x
Asset Growth %	0.63%	0.05%	2.18%	-0.33%	-0.05%	-0.05%	0.51%	-0.07%	0.02%	0.24%
Total Current Liabilities+	9.59M	8.87M	8.09M	14.44M	15.06M	16.48M	17.61M	17.87M	20.62M	17.95M
Accounts Payable	6.22M	5.98M	3.72M	9.55M	9.63M	9.45M	10.42M	9.68M	10.23M	8.53M
Days Payables Outstanding	219.49	193.55	126.58	224.81	171.21	143.74	146.55	120.77	113.9	81.87
Short-Term Debt	1.53M	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	272K	389.01K	314K	275K	169K	278K	161K	157K	195K	611K
Other Current Liabilities	39.53K	76.22K	114K	0	0	0	0	0	0	0
Current Ratio	1.73x	1.77x	7.07x	2.53x	2.23x	1.96x	2.78x	2.61x	2.40x	3.57x
Quick Ratio	0.87x	0.88x	6.35x	1.96x	1.46x	1.25x	2.00x	1.78x	1.70x	3.06x
Cash Conversion Cycle	118.77	161.22	162.59	20.48	51.1	50.65	72.97	105.33	70.65	34.86
Total Non-Current Liabilities+	3.89M	908.56K	802K	614K	4.74M	5.46M	8.5M	7.52M	5.89M	4.24M
Long-Term Debt	3.35M	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	444.59K	343.59K	310K	137K	866K	1.02M	4.15M	3.56M	2.58M	1.66M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	97.99K	564.97K	492K	477K	0	0	0	0	0	0
Total Liabilities	13.47M	9.78M	8.89M	15.05M	19.8M	21.93M	26.11M	25.39M	26.51M	22.18M
Total Debt+	5.54M	599.05K	506K	310K	1.72M	1.64M	4.7M	4.26M	3.28M	2.65M
Net Debt	-11.48K	-1.04M	-44.88M	-22.11M	-16.89M	-14.86M	-23.32M	-16.03M	-23.9M	-41.86M
Debt / Equity	1.05x	0.06x	0.01x	0.01x	0.08x	0.10x	0.15x	0.15x	0.12x	0.06x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	0.29x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-4.54x
Interest Coverage	-3.35x	-7.81x	-107.04x	-419.90x	-36.95x	-279.63x	-492.24x	-	-	-
Total Equity+	5.27M	9.97M	53.83M	27.18M	20.45M	16.42M	31.73M	28.67M	28.46M	46.09M
Equity Growth %	0.32%	0.89%	4.4%	-0.5%	-0.25%	-0.2%	0.93%	-0.1%	-0.01%	0.62%
Book Value per Share	0.15	0.27	1.21	0.49	0.36	0.27	0.47	0.41	0.38	0.58
Total Shareholders' Equity	5.27M	9.97M	53.83M	27.18M	20.45M	16.42M	31.73M	28.67M	28.46M	46.09M
Common Stock	36K	37.55K	55K	55K	60K	62K	68K	74K	75K	77K
Retained Earnings	-42.3M	-45.22M	-56.6M	-89.75M	-121.9M	-141.82M	-168.95M	-185.49M	-190.46M	-181.91M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	-3K	-2K	-3K	-4K	-4K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.11M	-2.94M	-9.8M	-20.91M	-20.44M	-10.6M	-24.16M	-15.1M	7.12M	12.11M
Operating CF Margin %	-0.12%	-0.14%	-0.46%	-0.66%	-0.44%	-0.18%	-0.36%	-0.21%	0.09%	0.12%
Operating CF Growth %	0.18%	-0.39%	-2.34%	-1.13%	0.02%	0.48%	-1.28%	0.38%	1.47%	0.7%
Net Income	-2.77M	-2.93M	-11.38M	-33.32M	-32.15M	-19.93M	-27.13M	-16.54M	-4.94M	8.55M
Depreciation & Amortization	330.55K	419.56K	716K	842K	1.52M	1.51M	1.63M	1.88M	1.71M	1.48M
Stock-Based Compensation	1.98M	1.19M	4.61M	6.37M	7.17M	6.94M	6.2M	5.74M	4.75M	3.66M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	557.42K	1.14M	-5.75M	4K	2.59M	-204K	-124K	-167K	977K	-4.71M
Working Capital Changes	-2.21M	-2.77M	2M	5.19M	427K	1.08M	-4.73M	-6.01M	4.62M	3.13M
Change in Receivables	-873.73K	-4.11M	937K	1.11M	-44K	-555K	-2.58M	-3.32M	2.25M	-1.28M
Change in Inventory	-4.44M	240.85K	2.18M	-2.45M	-3.29M	-148K	-1.92M	-1.08M	152K	5.33M
Change in Payables	2.77M	-245.67K	-2.36M	5.83M	78K	-181K	978K	-744K	553K	-1.07M
Cash from Investing+	-647.73K	-1.72M	4.6M	-1.77M	-249K	-165K	-409K	-334K	-143K	-143K
Capital Expenditures	-525.23K	-1.5M	-1.17M	-1.32M	-743K	-124K	-409K	-334K	-148K	-163K
CapEx % of Revenue	0.03%	0.07%	0.06%	0.04%	0.02%	0%	0.01%	0%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-122.5K	-220K	5.77M	-454K	494K	-41K	0	0	5K	20K
Cash from Financing+	4.34M	754.27K	48.95M	-90K	16.88M	8.65M	36.09M	7.65M	-90K	5.37M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	79.85K	258.68K	2.96M	510K	388K	4.07M	9.38M	-77K	-75K	-52K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-2.76M	-4.66M	-11.15M	-22.36M	-21.19M	-10.74M	-24.57M	-15.43M	6.97M	11.95M
FCF Margin %	-0.15%	-0.22%	-0.53%	-0.71%	-0.46%	-0.18%	-0.36%	-0.21%	0.08%	0.12%
FCF Growth %	0.03%	-0.69%	-1.39%	-1%	0.05%	0.49%	-1.29%	0.37%	1.45%	0.71%
FCF per Share	-0.08	-0.12	-0.25	-0.41	-0.37	-0.18	-0.37	-0.22	0.09	0.15
FCF Conversion (FCF/Net Income)	0.76x	1.00x	0.86x	0.63x	0.64x	0.53x	0.89x	0.91x	-1.44x	1.42x
Interest Paid	427.59K	261.74K	57K	41K	33K	13K	1K	1K	2K	1K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-59.77%	-38.4%	-35.66%	-82.25%	-135.01%	-108.09%	-112.68%	-54.77%	-17.29%	22.94%
Return on Invested Capital (ROIC)	-38.41%	-30.7%	-137.38%	-354.83%	-544.41%	-582.11%	-407.15%	-132.74%	-48.83%	131.74%
Gross Margin	42.13%	47.96%	49.42%	50.88%	55.67%	59.53%	61.51%	59.4%	60.76%	61.84%
Net Margin	-15.49%	-13.52%	-53.67%	-105.57%	-69.45%	-33.62%	-40.22%	-22.96%	-5.91%	8.58%
Debt / Equity	1.05x	0.06x	0.01x	0.01x	0.08x	0.10x	0.15x	0.15x	0.12x	0.06x
Interest Coverage	-3.35x	-7.81x	-107.04x	-419.90x	-36.95x	-279.63x	-492.24x	-	-	-
FCF Conversion	0.76x	1.00x	0.86x	0.63x	0.64x	0.53x	0.89x	0.91x	-1.44x	1.42x
Revenue Growth	16.79%	21.13%	-2.14%	48.85%	46.69%	28.01%	13.82%	6.82%	15.99%	19.18%

Frequently Asked Questions

Valuation & Price

Niagen Bioscience Inc (NAGE) has a price-to-earnings (P/E) ratio of 57.4x. This suggests investors expect higher future growth.

Growth & Financials

Niagen Bioscience Inc (NAGE) reported $124.7M in revenue for fiscal year 2024. This represents a 1437% increase from $8.1M in 2011.

Niagen Bioscience Inc (NAGE) grew revenue by 19.2% over the past year. This is strong growth.

Yes, Niagen Bioscience Inc (NAGE) is profitable, generating $20.4M in net income for fiscal year 2024 (8.6% net margin).

Dividend & Returns

Niagen Bioscience Inc (NAGE) has a return on equity (ROE) of 22.9%. This is excellent, indicating efficient use of shareholder capital.

Niagen Bioscience Inc (NAGE) generated $21.1M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Niagen Bioscience Inc (NAGE) 10-Year Financial Performance & Capital Metrics

NAGE • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AboutNiagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.Show more

Revenue $100M +19.2%
EBITDA $9M +336.5%
Net Income $9M +273.1%
EPS (Diluted) 0.11 +266.9%
Gross Margin 61.84% +1.8%
EBITDA Margin 9.25% +298.5%
Operating Margin 7.76% +215.8%
Net Margin 8.58% +245.3%
ROE 22.94% +232.7%
ROIC 131.74% +369.8%
Debt/Equity 0.06 -50.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong Piotroski F-Score: 7/9
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 16.6%
✓Efficient asset utilization: 1.5x turnover

✗Weaknesses

✗Weak momentum: RS Rating 12 (bottom 12%)
✗Trading more than 30% below 52-week high
✗Expensive at 10.9x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y20.59%

5Y16.56%

3Y13.87%

TTM36.04%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM1275.69%

EPS CAGR

10Y-

5Y-

3Y-

TTM1172.49%

ROCE

10Y Avg-52.19%

5Y Avg-43.59%

3Y Avg-15.46%

Latest18.25%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	17.88M	21.66M	21.2M	31.56M	46.29M	59.26M	67.45M	72.05M	83.57M	99.6M
Revenue Growth %	0.17%	0.21%	-0.02%	0.49%	0.47%	0.28%	0.14%	0.07%	0.16%	0.19%
Cost of Goods Sold+	10.35M	11.27M	10.72M	15.5M	20.52M	23.98M	25.96M	29.25M	32.79M	38.01M
COGS % of Revenue	0.58%	0.52%	0.51%	0.49%	0.44%	0.4%	0.38%	0.41%	0.39%	0.38%
Gross Profit+	7.53M	10.39M	10.48M	16.05M	25.77M	35.27M	41.49M	42.8M	50.78M	61.59M
Gross Margin %	0.42%	0.48%	0.49%	0.51%	0.56%	0.6%	0.62%	0.59%	0.61%	0.62%
Gross Profit Growth %	0.41%	0.38%	0.01%	0.53%	0.61%	0.37%	0.18%	0.03%	0.19%	0.21%
Operating Expenses+	9.6M	13.3M	26.85M	49.23M	57.07M	55.13M	68.56M	61.42M	56.38M	53.86M
OpEx % of Revenue	0.54%	0.61%	1.27%	1.56%	1.23%	0.93%	1.02%	0.85%	0.67%	0.54%
Selling, General & Admin	8.71M	10.77M	22.1M	43.67M	52.52M	51.71M	64.73M	56.6M	51.42M	47.84M
SG&A % of Revenue	0.49%	0.5%	1.04%	1.38%	1.13%	0.87%	0.96%	0.79%	0.62%	0.48%
Research & Development	891.6K	2.52M	4.01M	5.48M	4.42M	3.42M	3.83M	4.83M	4.96M	6.02M
R&D % of Revenue	0.05%	0.12%	0.19%	0.17%	0.1%	0.06%	0.06%	0.07%	0.06%	0.06%
Other Operating Expenses	0	0	746K	75K	125K	0	0	0	0	0
Operating Income+	-2.07M	-2.91M	-16.38M	-33.17M	-31.3M	-19.85M	-27.07M	-18.63M	-5.6M	7.73M
Operating Margin %	-0.12%	-0.13%	-0.77%	-1.05%	-0.68%	-0.34%	-0.4%	-0.26%	-0.07%	0.08%
Operating Income Growth %	0.61%	-0.41%	-4.64%	-1.03%	0.06%	0.37%	-0.36%	0.31%	0.7%	2.38%
EBITDA+	-1.74M	-2.49M	-15.66M	-32.33M	-29.78M	-18.34M	-25.45M	-16.74M	-3.89M	9.21M
EBITDA Margin %	-0.1%	-0.11%	-0.74%	-1.02%	-0.64%	-0.31%	-0.38%	-0.23%	-0.05%	0.09%
EBITDA Growth %	0.65%	-0.43%	-5.3%	-1.06%	0.08%	0.38%	-0.39%	0.34%	0.77%	3.37%
D&A (Non-Cash Add-back)	330.55K	419.56K	716K	842K	1.52M	1.51M	1.63M	1.88M	1.71M	1.48M
EBIT	-2.07M	-2.91M	-16.38M	-33.17M	-31.3M	-19.85M	-27.07M	-18.63M	-5.6M	7.73M
Net Interest Income+	-612.71K	-333.29K	-153K	-79K	-847K	-71K	-55K	3K	661K	1.13M
Interest Income	3.33K	2.25K	0	0	0	0	0	3K	661K	1.13M
Interest Expense	616.03K	371.9K	153K	79K	847K	71K	55K	0	0	0
Other Income/Expense	-566.92K	-646.38K	-153K	-144K	-847K	-71K	-55K	2.09M	661K	1.13M
Pretax Income+	-2.63M	-3.55M	-16.53M	-33.32M	-32.15M	-19.93M	-27.13M	-16.54M	-4.94M	8.86M
Pretax Margin %	-0.15%	-0.16%	-0.78%	-1.06%	-0.69%	-0.34%	-0.4%	-0.23%	-0.06%	0.09%
Income Tax+	4.53K	0	0	0	0	0	0	0	0	305K
Effective Tax Rate %	1.05%	0.82%	0.69%	1%	1%	1%	1%	1%	1%	0.97%
Net Income+	-2.77M	-2.93M	-11.38M	-33.32M	-32.15M	-19.93M	-27.13M	-16.54M	-4.94M	8.55M
Net Margin %	-0.15%	-0.14%	-0.54%	-1.06%	-0.69%	-0.34%	-0.4%	-0.23%	-0.06%	0.09%
Net Income Growth %	0.49%	-0.06%	-2.89%	-1.93%	0.04%	0.38%	-0.36%	0.39%	0.7%	2.73%
Net Income (Continuing)	-2.64M	-3.55M	-16.53M	-33.32M	-32.15M	-19.93M	-27.13M	-16.54M	-4.94M	8.55M
Discontinued Operations	-133.53K	623.41K	5.15M	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.08	-0.08	-0.26	-0.61	-0.56	-0.33	-0.40	-0.24	-0.07	0.11
EPS Growth %	0.49%	-0.02%	-2.31%	-1.35%	0.08%	0.41%	-0.21%	0.4%	0.73%	2.67%
EPS (Basic)	-0.08	-0.08	-0.26	-0.61	-0.56	-0.33	-0.40	-0.24	-0.07	0.10
Diluted Shares Outstanding	35.88M	37.29M	44.6M	55.01M	57.06M	61.07M	67.19M	69.73M	74.98M	79.72M
Basic Shares Outstanding	35.88M	37.29M	44.6M	55.01M	57.06M	61.07M	67.19M	68.92M	70.54M	85.42M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	16.55M	15.74M	57.18M	36.53M	33.52M	32.22M	48.91M	46.57M	49.53M	64.1M
Cash & Short-Term Investments	5.55M	1.64M	45.39M	22.42M	18.61M	16.5M	28.02M	20.29M	27.17M	44.51M
Cash Only	5.55M	1.64M	45.39M	22.42M	18.61M	16.5M	28.02M	20.29M	27.17M	44.51M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	2.45M	5.85M	5.34M	4.42M	2.17M	2.69M	5.23M	8.48M	5.23M	7.77M
Days Sales Outstanding	50.01	98.59	91.9	51.07	17.15	16.59	28.28	42.97	22.86	28.47
Inventory	8.17M	7.91M	5.8M	8.25M	11.54M	11.68M	13.6M	14.68M	14.53M	9.19M
Days Inventory Outstanding	288.25	256.17	197.27	194.23	205.16	177.8	191.24	183.13	161.68	88.27
Other Current Assets	0	18.32K	0	877K	200K	200K	200K	3.12M	2.6M	2.63M
Total Non-Current Assets+	2.2M	4.01M	5.54M	5.7M	6.73M	6.14M	8.94M	7.49M	5.43M	4.18M
Property, Plant & Equipment	1.79M	1.78M	2.87M	3.58M	4.66M	4.43M	7.36M	6.32M	4.54M	3.45M
Fixed Asset Turnover	10.00x	12.18x	7.38x	8.80x	9.94x	13.37x	9.17x	11.40x	18.42x	28.88x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	354K	486K	1.65M	1.55M	1.31M	1.08M	857K	671K	510K	359K
Long-Term Investments	0	20.32K	0	0	0	0	0	0	0	0
Other Non-Current Assets	58.88K	1.73M	1.02M	566K	762K	625K	723K	497K	383K	368K
Total Assets+	18.75M	19.75M	62.72M	42.23M	40.25M	38.36M	57.84M	54.06M	54.96M	68.28M
Asset Turnover	0.95x	1.10x	0.34x	0.75x	1.15x	1.54x	1.17x	1.33x	1.52x	1.46x
Asset Growth %	0.63%	0.05%	2.18%	-0.33%	-0.05%	-0.05%	0.51%	-0.07%	0.02%	0.24%
Total Current Liabilities+	9.59M	8.87M	8.09M	14.44M	15.06M	16.48M	17.61M	17.87M	20.62M	17.95M
Accounts Payable	6.22M	5.98M	3.72M	9.55M	9.63M	9.45M	10.42M	9.68M	10.23M	8.53M
Days Payables Outstanding	219.49	193.55	126.58	224.81	171.21	143.74	146.55	120.77	113.9	81.87
Short-Term Debt	1.53M	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	272K	389.01K	314K	275K	169K	278K	161K	157K	195K	611K
Other Current Liabilities	39.53K	76.22K	114K	0	0	0	0	0	0	0
Current Ratio	1.73x	1.77x	7.07x	2.53x	2.23x	1.96x	2.78x	2.61x	2.40x	3.57x
Quick Ratio	0.87x	0.88x	6.35x	1.96x	1.46x	1.25x	2.00x	1.78x	1.70x	3.06x
Cash Conversion Cycle	118.77	161.22	162.59	20.48	51.1	50.65	72.97	105.33	70.65	34.86
Total Non-Current Liabilities+	3.89M	908.56K	802K	614K	4.74M	5.46M	8.5M	7.52M	5.89M	4.24M
Long-Term Debt	3.35M	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	444.59K	343.59K	310K	137K	866K	1.02M	4.15M	3.56M	2.58M	1.66M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	97.99K	564.97K	492K	477K	0	0	0	0	0	0
Total Liabilities	13.47M	9.78M	8.89M	15.05M	19.8M	21.93M	26.11M	25.39M	26.51M	22.18M
Total Debt+	5.54M	599.05K	506K	310K	1.72M	1.64M	4.7M	4.26M	3.28M	2.65M
Net Debt	-11.48K	-1.04M	-44.88M	-22.11M	-16.89M	-14.86M	-23.32M	-16.03M	-23.9M	-41.86M
Debt / Equity	1.05x	0.06x	0.01x	0.01x	0.08x	0.10x	0.15x	0.15x	0.12x	0.06x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	0.29x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-4.54x
Interest Coverage	-3.35x	-7.81x	-107.04x	-419.90x	-36.95x	-279.63x	-492.24x	-	-	-
Total Equity+	5.27M	9.97M	53.83M	27.18M	20.45M	16.42M	31.73M	28.67M	28.46M	46.09M
Equity Growth %	0.32%	0.89%	4.4%	-0.5%	-0.25%	-0.2%	0.93%	-0.1%	-0.01%	0.62%
Book Value per Share	0.15	0.27	1.21	0.49	0.36	0.27	0.47	0.41	0.38	0.58
Total Shareholders' Equity	5.27M	9.97M	53.83M	27.18M	20.45M	16.42M	31.73M	28.67M	28.46M	46.09M
Common Stock	36K	37.55K	55K	55K	60K	62K	68K	74K	75K	77K
Retained Earnings	-42.3M	-45.22M	-56.6M	-89.75M	-121.9M	-141.82M	-168.95M	-185.49M	-190.46M	-181.91M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	-3K	-2K	-3K	-4K	-4K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.11M	-2.94M	-9.8M	-20.91M	-20.44M	-10.6M	-24.16M	-15.1M	7.12M	12.11M
Operating CF Margin %	-0.12%	-0.14%	-0.46%	-0.66%	-0.44%	-0.18%	-0.36%	-0.21%	0.09%	0.12%
Operating CF Growth %	0.18%	-0.39%	-2.34%	-1.13%	0.02%	0.48%	-1.28%	0.38%	1.47%	0.7%
Net Income	-2.77M	-2.93M	-11.38M	-33.32M	-32.15M	-19.93M	-27.13M	-16.54M	-4.94M	8.55M
Depreciation & Amortization	330.55K	419.56K	716K	842K	1.52M	1.51M	1.63M	1.88M	1.71M	1.48M
Stock-Based Compensation	1.98M	1.19M	4.61M	6.37M	7.17M	6.94M	6.2M	5.74M	4.75M	3.66M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	557.42K	1.14M	-5.75M	4K	2.59M	-204K	-124K	-167K	977K	-4.71M
Working Capital Changes	-2.21M	-2.77M	2M	5.19M	427K	1.08M	-4.73M	-6.01M	4.62M	3.13M
Change in Receivables	-873.73K	-4.11M	937K	1.11M	-44K	-555K	-2.58M	-3.32M	2.25M	-1.28M
Change in Inventory	-4.44M	240.85K	2.18M	-2.45M	-3.29M	-148K	-1.92M	-1.08M	152K	5.33M
Change in Payables	2.77M	-245.67K	-2.36M	5.83M	78K	-181K	978K	-744K	553K	-1.07M
Cash from Investing+	-647.73K	-1.72M	4.6M	-1.77M	-249K	-165K	-409K	-334K	-143K	-143K
Capital Expenditures	-525.23K	-1.5M	-1.17M	-1.32M	-743K	-124K	-409K	-334K	-148K	-163K
CapEx % of Revenue	0.03%	0.07%	0.06%	0.04%	0.02%	0%	0.01%	0%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-122.5K	-220K	5.77M	-454K	494K	-41K	0	0	5K	20K
Cash from Financing+	4.34M	754.27K	48.95M	-90K	16.88M	8.65M	36.09M	7.65M	-90K	5.37M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	79.85K	258.68K	2.96M	510K	388K	4.07M	9.38M	-77K	-75K	-52K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-2.76M	-4.66M	-11.15M	-22.36M	-21.19M	-10.74M	-24.57M	-15.43M	6.97M	11.95M
FCF Margin %	-0.15%	-0.22%	-0.53%	-0.71%	-0.46%	-0.18%	-0.36%	-0.21%	0.08%	0.12%
FCF Growth %	0.03%	-0.69%	-1.39%	-1%	0.05%	0.49%	-1.29%	0.37%	1.45%	0.71%
FCF per Share	-0.08	-0.12	-0.25	-0.41	-0.37	-0.18	-0.37	-0.22	0.09	0.15
FCF Conversion (FCF/Net Income)	0.76x	1.00x	0.86x	0.63x	0.64x	0.53x	0.89x	0.91x	-1.44x	1.42x
Interest Paid	427.59K	261.74K	57K	41K	33K	13K	1K	1K	2K	1K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-59.77%	-38.4%	-35.66%	-82.25%	-135.01%	-108.09%	-112.68%	-54.77%	-17.29%	22.94%
Return on Invested Capital (ROIC)	-38.41%	-30.7%	-137.38%	-354.83%	-544.41%	-582.11%	-407.15%	-132.74%	-48.83%	131.74%
Gross Margin	42.13%	47.96%	49.42%	50.88%	55.67%	59.53%	61.51%	59.4%	60.76%	61.84%
Net Margin	-15.49%	-13.52%	-53.67%	-105.57%	-69.45%	-33.62%	-40.22%	-22.96%	-5.91%	8.58%
Debt / Equity	1.05x	0.06x	0.01x	0.01x	0.08x	0.10x	0.15x	0.15x	0.12x	0.06x
Interest Coverage	-3.35x	-7.81x	-107.04x	-419.90x	-36.95x	-279.63x	-492.24x	-	-	-
FCF Conversion	0.76x	1.00x	0.86x	0.63x	0.64x	0.53x	0.89x	0.91x	-1.44x	1.42x
Revenue Growth	16.79%	21.13%	-2.14%	48.85%	46.69%	28.01%	13.82%	6.82%	15.99%	19.18%

Frequently Asked Questions

Valuation & Price

Niagen Bioscience Inc (NAGE) has a price-to-earnings (P/E) ratio of 57.4x. This suggests investors expect higher future growth.

Growth & Financials

Niagen Bioscience Inc (NAGE) reported $124.7M in revenue for fiscal year 2024. This represents a 1437% increase from $8.1M in 2011.

Niagen Bioscience Inc (NAGE) grew revenue by 19.2% over the past year. This is strong growth.

Yes, Niagen Bioscience Inc (NAGE) is profitable, generating $20.4M in net income for fiscal year 2024 (8.6% net margin).

Dividend & Returns

Niagen Bioscience Inc (NAGE) has a return on equity (ROE) of 22.9%. This is excellent, indicating efficient use of shareholder capital.

Niagen Bioscience Inc (NAGE) generated $21.1M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.